Ticker >

Indoco Remedies share price

Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs  40k   133   14

331.20
-1.25 (-0.38%)
BSE: Today, 03:15 PM

Price Summary

Today's High

₹ 335.7

Today's Low

₹ 328.35

52 Week High

₹ 416.95

52 Week Low

₹ 307

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3053.07 Cr.

Enterprise Value

3355.18 Cr.

No. of Shares

9.22 Cr.

P/E

29.23

P/B

2.81

Face Value

₹ 2

Div. Yield

0.68 %

Book Value (TTM)

₹  117.89

CASH

12.4 Cr.

DEBT

314.5 Cr.

Promoter Holding

58.72 %

EPS (TTM)

₹  11.33

Sales Growth

8.25%

ROE

14.64 %

ROCE

17.42%

Profit Growth

-8.52 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Indoco Remedies Ltd.

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.25%
3 Year14.65%
5 Year9.93%

Profit Growth

1 Year-8.52%
3 Year79.98%
5 Year27.97%

ROE%

1 Year14.64%
3 Year15.29%
5 Year9.81%

ROCE %

1 Year17.42%
3 Year18.77%
5 Year12.67%

Debt/Equity

0.3064

Price to Cash Flow

17.39

Interest Cover Ratio

8.58206332685633

CFO/PAT (5 Yr. Avg.)

1.67473015065576

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 58.72 0
Dec 2023 58.74 0
Sep 2023 58.74 0
Jun 2023 58.73 0
Mar 2023 58.69 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 79.9772546122447% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 8.58206332685633.
  • The company has an efficient Cash Conversion Cycle of 48.9894428219353 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.67473015065576.
  • The company has a high promoter holding of 58.72%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.23832494833311.

 Limitations

  • The company has shown a poor revenue growth of 14.6480670510479% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 398.64 427.46 422.88 473.39 449.05
Total Expenditure 336.99 363.29 359.97 400.97 383.76
Operating Profit 61.65 64.17 62.91 72.42 65.29
Other Income 0.37 0.49 0.41 1.12 2.93
Interest 7.01 8.64 7.78 8.1 10.03
Depreciation 17.16 17.69 19.87 21.41 22.97
Exceptional Items 0 0 0 0 -8.2
Profit Before Tax 37.85 38.33 35.67 44.03 27.02
Tax 9.98 12.96 9.73 10.89 7.01
Profit After Tax 27.87 25.37 25.94 33.14 20.01
Adjusted EPS (Rs) 3.02 2.75 2.82 3.6 2.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 967.73 1105.99 1240.3 1539.72 1666.69
Total Expenditure 891.03 985.01 1022.67 1213.81 1381.85
Operating Profit 76.7 120.98 217.63 325.91 284.84
Other Income 6.71 4.79 9.05 6.71 2.62
Interest 21.09 26.25 22.22 17.43 25.27
Depreciation 71.56 70.81 73.12 78.95 70.6
Exceptional Items 0 0 0 0 0
Profit Before Tax -9.24 28.71 131.35 236.23 191.59
Tax -6.4 4.46 38.96 81.71 50.23
Net Profit -2.84 24.25 92.39 154.52 141.36
Adjusted EPS (Rs.) -0.31 2.63 10.03 16.77 15.34

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.43 18.43
Total Reserves 642.65 661.73 750.5 885.87 1008.59
Borrowings 128.66 96.93 96.94 95.88 143.5
Other N/C liabilities -12.31 3.98 61.36 60.68 117.12
Current liabilities 445.33 459.17 408.54 519.93 427.24
Total Liabilities 1222.76 1240.24 1335.76 1580.8 1714.87
Assets
Net Block 467.52 589.62 569.91 554.98 661.46
Capital WIP 141.23 7.32 25.12 52.82 54.36
Intangible WIP 44.2 43.38 42.98 68.72 58.21
Investments 2.44 2.45 2.45 2.46 18.9
Loans & Advances 29.3 34.02 71.29 33.68 112.65
Other N/C Assets 1.56 1.68 2.05 2.13 2.25
Current Assets 536.5 561.76 621.95 866.01 807.05
Total Assets 1222.76 1240.24 1335.76 1580.8 1714.87
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -9.24 28.71 131.35 236.23 191.59
Adjustment 89.34 99.51 109.71 87.12 120.88
Changes in Assets & Liabilities 55.66 -1.65 -139.14 -108.81 -75.49
Tax Paid -3.62 -3.92 -19.75 -40.99 -61.38
Operating Cash Flow 132.13 122.66 82.17 173.55 175.59
Investing Cash Flow -103.76 -55.95 -66.7 -121.41 -205.31
Financing Cash Flow -16.14 -63.95 -29.83 -44.37 22.81
Net Cash Flow 12.23 2.76 -14.35 7.77 -6.91

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 58.69 58.73 58.74 58.74 58.72
kare aruna suresh 5.20 5.20 5.20 5.20 5.20
kare suresh govind 4.41 4.41 4.41 4.41 4.40
madhura suresh kare - - 5.64 5.64 5.64
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
megh milind panandikar 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 0.01 0.01 0.01 0.01
panandikar aditi milind 6.03 6.06 6.07 6.07 6.07
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.12 17.12 17.12 17.12 17.11
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
spa holdings pvt ltd 19.90 19.90 19.90 19.90 19.89
sudha m pai 0.01 0.01 0.01 0.01 0.01
suresh govind kare huf ... - - 0.30 0.30 0.30
ramani madhura anup 5.63 5.64 - - -
suresh govind kare huf - 0.30 - - -
suresh govind kare huf (k... 0.30 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 41.31 41.27 41.26 41.26 41.28
dsp healthcare fund 1.37 1.37 1.37 1.51 1.84
franklin india smaller co... 1.45 1.45 1.48 1.48 1.48
hdfc trustee company ltd ... - - 1.32 1.63 1.63
icici prudential smallcap... 3.58 3.87 4.42 2.21 1.91
independent director - - 0.02 - 0.02
investor education and pr... - - 0.11 - 0.11
llp 0.12 0.13 0.10 0.06 0.05
mangeshi investment priva... 1.27 1.27 1.27 1.27 1.27
nippon life india trustee... 4.97 4.97 4.97 4.97 4.97
quant mutual fund-quant s... - - - 4.45 4.56
uti healthcare fund - 1.22 1.18 1.07 1.05
investor education and pr... 0.11 0.11 - 0.11 -
aditya birla sun life tru... 2.20 2.15 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Indoco Remedies informs about corporate guarantee 5 Apr 2024, 4:52PM Indoco Remedies’ arm commences commercial production of Pharmaceutical Intermediates26 Mar 2024, 9:58AM Indoco Remedies gets nod to purchase land in Mumbai12 Mar 2024, 5:11PM Indoco Remedies informs about press release2 Mar 2024, 12:18PM Indoco Remedies’ arm starts commercial production of oral care products2 Mar 2024, 11:36AM Indoco Remedies informs about newspaper publication24 Jan 2024, 4:35PM Indoco Remedies - Quaterly Results23 Jan 2024, 12:29PM Indoco Remedies - Quaterly Results23 Jan 2024, 12:29PM Indoco Remedies - Quaterly Results23 Jan 2024, 12:29PM Indoco Remedies gets EIR for Goa manufacturing facility from USFDA18 Jan 2024, 5:11PM Indoco Remedies informs about receipt of establishment inspection report18 Jan 2024, 5:05PM Indoco Remedies receives USFDA’s approval for Canagliflozin Tablets6 Dec 2023, 3:27PM Indoco Remedies informs about press release20 Oct 2023, 2:51PM Indoco Remedies informs about outcome of board meeting19 Oct 2023, 3:13PM Indoco Remedies informs about issuance of corporate guarantee19 Oct 2023, 2:17PM Indoco Remedies - Quaterly Results19 Oct 2023, 12:12PM Indoco Remedies - Quaterly Results19 Oct 2023, 12:12PM Indoco Remedies - Quaterly Results19 Oct 2023, 12:12PM Indoco Remedies informs about cut-off date for e- voting and book closure date1 Sep 2023, 10:18AM Indoco Remedies informs about AGM and annual report 1 Sep 2023, 10:15AM Indoco remedies informs about update on fire accident28 Aug 2023, 12:56PM Indoco Remedies informs about analyst meet18 Aug 2023, 12:44PM Indoco Remedies informs about transcript of conference call28 Jul 2023, 12:22PM Indoco Remedies informs about press release26 Jul 2023, 12:52PM Indoco Remedies informs about press release26 Jul 2023, 12:37PM Indoco Remedies gets EU GMP certification for Baddi manufacturing site26 Jul 2023, 11:51AM Indoco Remedies reports 37% fall in Q1 consolidated net profit25 Jul 2023, 4:58PM Indoco Remedies informs about unaudited financial results 25 Jul 2023, 4:34PM Indoco Remedies - Quaterly Results25 Jul 2023, 11:45AM Indoco Remedies - Quaterly Results25 Jul 2023, 11:45AM Indoco Remedies - Quaterly Results25 Jul 2023, 11:45AM Indoco Remedies gets EU GMP certification for Goa manufacturing site11 Jul 2023, 4:11PM Indoco Remedies informs about disclosure 13 Jun 2023, 5:21PM Indoco Remedies informs about disclosure12 Jun 2023, 4:56PM Indoco Remedies gets EU GMP certification for Baddi facility9 Jun 2023, 2:30PM Indoco Remedies informs about execution of equity purchase agreement6 Jun 2023, 9:42AM Indoco Remedies acquires 85% stake in FPP Holding Company6 Jun 2023, 9:29AM USFDA issues 4 observations to Indoco Remedies’ Sterile facility at Goa5 Jun 2023, 10:22AM Indoco Remedies informs about updates 3 Jun 2023, 10:02AM Indoco Remedies informs about transcript of earnings call26 May 2023, 5:02PM Indoco Remedies reports 36% fall in Q4 consolidated net profit23 May 2023, 6:06PM Indoco Remedies - Quaterly Results23 May 2023, 1:38PM Indoco Remedies - Quaterly Results23 May 2023, 1:38PM Indoco Remedies - Quaterly Results23 May 2023, 1:38PM Indoco Remedies informs about press release3 May 2023, 11:21AM Indoco Remedies gets EIR from USFDA for manufacturing facility in Goa3 May 2023, 10:41AM Indoco Remedies informs about compliance certificate4 Apr 2023, 10:03AM USFDA conducts GMP inspection at Indoco Remedies’ Goa Facility 1 Mar 2023, 12:14PM Indoco Remedies informs about audio recording of conference21 Feb 2023, 3:33PM Indoco Remedies informs about audio recording of investors conference 14 Feb 2023, 11:59AM

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Indoco Remedies and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Indoco Remedies cash from the operating activity was Rs 175.5918 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Indoco Remedies has a Debt to Equity ratio of 0.3064 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Indoco Remedies , the EPS growth was -8.51661458457575 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Indoco Remedies has OPM of 17.0901194588487 % which is a good sign for profitability.
     
  • ROE: Indoco Remedies have a average ROE of 14.6438581489577 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Indoco Remedies is Rs 331.85. One can use valuation calculators of ticker to know if Indoco Remedies share price is undervalued or overvalued.
Last Updated on:
Brief about Indoco Remedies

Indoco Remedies Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Indoco Remedies Ltd. is a renowned pharmaceutical company with a strong presence in both domestic and international markets. With a legacy spanning several decades, the company has established itself as a key player in the pharmaceutical industry. Indoco Remedies Ltd. is known for its commitment to quality and innovation, and it operates across various therapeutic segments such as cardiovascular, anti-infectives, pain management, and more.

Indoco Remedies Ltd. - Share Price

The share price of Indoco Remedies Ltd. reflects the market's perception of the company's value and potential. Investors keen on analyzing the stock can track the share price using our pre-built screening tool, which provides real-time updates and historical data. By monitoring the share price, investors can identify trends, patterns, and potential buying or selling opportunities.

Indoco Remedies Ltd. - Balance Sheet

The balance sheet of Indoco Remedies Ltd. is a crucial financial statement that provides insights into the company's financial position. Investors can examine the company's assets, liabilities, and equity recorded on the balance sheet. To aid in the stock analysis process, our website offers premium features such as fair value calculations using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Indoco Remedies Ltd. - Annual Report

The annual report of Indoco Remedies Ltd. offers a comprehensive overview of the company's performance and achievements over the past year. It provides detailed information on the company's financials, operations, strategic initiatives, and future outlook. Investors can download the annual report from our website to gain an in-depth understanding of Indoco Remedies Ltd.'s progress and prospects.

Indoco Remedies Ltd. - Dividend

Dividends are an important consideration for long-term stock investors. Indoco Remedies Ltd. has a track record of rewarding its shareholders through regular dividend payouts. By analyzing the company's dividend history and policies, investors can gauge the company's commitment to sharing profits with its shareholders.

Indoco Remedies Ltd. - Quarterly Result

Keeping track of Indoco Remedies Ltd.'s quarterly results is essential for investors looking for timely and relevant information. Our website provides access to the company's quarterly reports, allowing investors to assess the company's performance, revenue, and profitability on a regular basis. Combining these reports with our pre-built screening tools can facilitate effective stock analysis.

Indoco Remedies Ltd. - Stock Price

Indoco Remedies Ltd.'s stock price is a dynamic indicator of market sentiment and investor perception. By analyzing historical stock price data and monitoring market trends, investors can identify potential trading opportunities. Our website offers real-time stock price updates, interactive price charts, and news to help investors make informed decisions.

Indoco Remedies Ltd. - Price Chart

Visual representation of Indoco Remedies Ltd.'s stock price movements can be insightful for investors. Our website features interactive price charts that enable users to track historical price trends, identify patterns, and analyze market behavior. Combined with our pre-built screening tools, investors can leverage price charts to enhance their stock analysis and decision-making.

Indoco Remedies Ltd. - News

Staying updated with the latest news and developments surrounding Indoco Remedies Ltd. is crucial for informed decision-making. Our website curates news articles and press releases related to the company, enabling investors to stay on top of industry trends, regulatory changes, product launches, and other market influences. Accessing relevant news can provide valuable insights for stock analysis.

Indoco Remedies Ltd. - Concall Transcripts

Concall transcripts offer detailed records of earnings conference calls conducted by Indoco Remedies Ltd. By accessing these transcripts through our website, investors gain access to management discussions, insights, and future guidance. These insights combined with our pre-built screening tools can enhance stock analysis and aid in understanding the company's strategic outlook.

Indoco Remedies Ltd. - Investor Presentations

Investor presentations provide a comprehensive overview of Indoco Remedies Ltd.'s business strategies, financial performance, and growth potential. By studying investor presentations available for download on our website, investors can gain deeper insights into the company's value proposition, market positioning, and future plans. Access to these presentations enhances the stock analysis process.

Indoco Remedies Ltd. - Promoters

Indoco Remedies Ltd. owes its success to its dedicated promoters. The promoters play a significant role in shaping the company's growth and strategy. Investors can evaluate the credibility and track record of the promoters to gain insights into the company's leadership and long-term vision.

Indoco Remedies Ltd. - Shareholders

Understanding the shareholders and their holdings in Indoco Remedies Ltd. can provide insights into the company's ownership structure and potential influence. Investors can analyze the shareholding patterns and identify key stakeholders who have a significant interest in the company. Such analysis can aid in evaluating the company's stability and potential for growth.

Remember, for detailed financial data points, numbers, and analyses, we recommend referring to the downloadable annual reports, concall transcripts, investor presentations, credit ratings, and research reports available on our website. Our premium features, such as fair value calculation tools, can further enhance your stock analysis. Stay abreast of the latest news, track the share price, and leverage our pre-built screening tools for a comprehensive analysis of Indoco Remedies Ltd.'s stock.

Read More
X